Adversarial Injection · Belzutifan (Welireg; PT2977; MK-6482; NDA 215258; CAS 1672668-24-4; MW ~373.4 g/mol; benzamide-oxazolyl scaffold [FORTY-THIRD MECHANISM CLASS in Glyphward 600-attack portfolio — FIRST HIF-2α (EPAS1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1) INHIBITOR EVER FDA APPROVED: prior to NDA 215258 (August 13 2021), no HIF-2α inhibitor or hypoxia-inducible factor inhibitor of any kind had received FDA approval; HIF-2α (EPAS1; gene EPAS1 on chr2p21) is NOT a kinase, NOT a GPCR, NOT an enzyme with an active site in the traditional sense — HIF-2α is a bHLH-PAS transcription factor that heterodimerizes with ARNT (HIF-1β; also bHLH-PAS) through PAS (PER-ARNT-SIM) domain interactions; under normoxia, HIF-α subunits are hydroxylated by PHD (prolyl hydroxylase domain) enzymes at conserved proline residues (HIF-2α Pro405/Pro531) → hydroxylated HIF-α recognized by pVHL (product of VHL tumor suppressor gene) as part of the CRL2 E3 ubiquitin ligase complex → poly-ubiquitination → 26S proteasomal degradation; under hypoxia, PHD enzymes are inactivated (Fe²⁺ oxidation; competitive HIF-2α substrate inhibition) → HIF-2α escapes degradation → accumulates → translocates to nucleus → heterodimerizes with ARNT at PAS-B domain → HIF-2α/ARNT heterodimer binds HREs (Hypoxia Response Elements; 5'-RCGTG-3') → transcribes VEGFA, VEGFB, EPO, CCND1, OCT4, PAX6 → promotes tumor angiogenesis, erythropoiesis, proliferation; IN VHL DISEASE: germline VHL mutation (autosomal dominant; von Hippel-Lindau tumor suppressor; ~7.7 million affected worldwide) → pVHL protein loss → ALL HIF-α isoforms escape PHD-dependent ubiquitination → constitutive HIF-2α accumulation in ALL cell types → constitutive VEGF/EPO transcription → ccRCC (clear cell renal cell carcinoma) in >70% of VHL patients + hemangioblastomas + pheochromocytomas/paragangliomas + pNETs; BELZUTIFAN MECHANISM: binds the PAS-B (PER-ARNT-SIM domain B) pocket of HIF-2α — a hydrophobic cryptic pocket at the HIF-2α PAS-B/ARNT PAS-B interaction interface — disrupts the HIF-2α/ARNT heterodimer assembly; prevents HIF-2α nuclear localization and HRE transcription; NOT kinase ATP competition, NOT GPCR binding, NOT enzyme active site — a true protein-protein interaction (PPI) inhibitor targeting a non-catalytic domain; PELOTON THERAPEUTICS ACQUISITION: Peloton Therapeutics Inc (Dallas TX; founded 2009; Kevin Gardner/Richard Bhatt) discovered PT2977 through structure-based fragment screening of the HIF-2α PAS-B pocket; Merck & Co Inc acquired Peloton Therapeutics April 2019 for $1.05 billion upfront ($2.2B total with milestones) — the largest single acquisition for a pre-approval drug in the 2019 biopharma M&A year; STUDY 004: Phase 2 (NCT03401788); VHL disease-associated ccRCC ORR 49% (n=61; mDoR not reached at 21-month follow-up); pancreatic lesion response rate 77%; PHEO/PGL response rate 91%; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Forty-Third Mechanism Class: First HIF-2α Inhibitor Ever + PAS-B Domain PPI Inhibitor + VHL Disease Multi-Tumor + Merck Peloton $1.05B + Study 004 ccRCC ORR 49% · Attack #600

Belzutifan (benzamide-oxazolyl scaffold; Welireg; PT2977; MK-6482; NDA 215258; CAS 1672668-24-4; MW ~373.4 g/mol; [FORTY-THIRD MECHANISM CLASS: FIRST HIF-2α (EPAS1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; bHLH-PAS TRANSCRIPTION FACTOR) INHIBITOR EVER FDA APPROVED (NDA 215258 August 13 2021; no prior HIF-2α or HIF-α inhibitor in any indication); FIRST HYPOXIA-INDUCIBLE FACTOR INHIBITOR; PAS-B DOMAIN HIF-2α/ARNT HETERODIMER INTERFACE PPI INHIBITOR (NOT a kinase; NOT a GPCR; NOT an enzyme active site; non-catalytic bHLH-PAS transcription factor domain); VHL DISEASE MULTI-TUMOR INDICATION (ccRCC + pheochromocytoma/paraganglioma + pNET; germline VHL mutation); PELOTON THERAPEUTICS DALLAS TX ACQUIRED MERCK $1.05B APRIL 2019; STUDY 004 VHL-ccRCC ORR 49% (n=61; mDoR not reached); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Merck & Co Inc Rahway NJ (NDA 215258 holder; MK-6482 Merck development; VHL/ccRCC oncology commercial), Peloton Therapeutics Inc Dallas TX (PT2977 discovery; PAS-B pocket structure-based drug design; Merck acquisition origin), and Cleveland Clinic Taussig Cancer Institute Cleveland OH (VHL disease surveillance program; ccRCC oncology pharmacist) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Forty-Third Mechanism Class + First HIF-2α Inhibitor Ever + PAS-B Domain PPI Inhibitor + VHL Disease: AI Prompt Injection via EHS Monitor Report AI

Belzutifan (CAS 1672668-24-4; NIOSH HD Category 1) is the forty-third distinct mechanism class in the Glyphward adversarial portfolio and the first HIF-2α (EPAS1) inhibitor ever approved by the FDA, introducing a target architecture with no prior representation in 599 prior attacks: HIF-2α is a bHLH-PAS (basic helix-loop-helix PER-ARNT-SIM) transcription factor — not a kinase, not a GPCR, not an enzyme with a traditional active site — that regulates hypoxic gene transcription by heterodimerizing with ARNT (HIF-1β; also bHLH-PAS) through their PAS-B domains. Belzutifan targets this HIF-2α/ARNT PAS-B domain interaction: by binding a cryptic hydrophobic pocket in the HIF-2α PAS-B domain (identified through NMR-guided fragment screening by Peloton Therapeutics), belzutifan sterically prevents HIF-2α/ARNT heterodimerization, blocking HRE-driven transcription of VEGFA, EPO, CCND1, and OCT4 — a true protein-protein interaction (PPI) inhibitor targeting a non-catalytic transcription factor domain. In VHL disease (germline VHL mutation; autosomal dominant; ~7.7 million affected worldwide), the pVHL protein is absent or dysfunctional, abolishing the PHD-dependent ubiquitination and proteasomal degradation of HIF-2α — resulting in constitutive HIF-2α accumulation and constitutive angiogenic/proliferative transcription that drives ccRCC (>70% of VHL patients), pheochromocytoma/paraganglioma, and pancreatic neuroendocrine tumors (pNET). The Study 004 trial (NCT03401788) demonstrated ORR 49% in VHL-associated ccRCC (n=61), with pancreatic lesion response 77% and pheochromocytoma/paraganglioma response 91% — the first systemic therapy specifically developed for VHL disease.

Belzutifan Forty-Third Mechanism Class: HIF-2α PAS-B Domain PPI Inhibitor, VHL Pathway Biology, and Peloton Discovery

Belzutifan (PT2977; MK-6482; CAS 1672668-24-4) represents the forty-third distinct mechanism class in the Glyphward portfolio, introducing HIF-2α (EPAS1; endothelial PAS domain-containing protein 1) — a bHLH-PAS transcription factor — as a new target architecture distinct from all 42 prior mechanism classes in the portfolio. The key structural feature of belzutifan's binding mechanism is the PAS-B (PER-ARNT-SIM domain B) cryptic pocket: HIF-2α contains two PAS domains (PAS-A and PAS-B); the PAS-B domain forms the primary heterodimerization interface with ARNT's PAS-B domain; this interface has a small (~350 ų) hydrophobic cavity that is absent in the structural homologue HIF-1α PAS-B (explaining belzutifan's HIF-2α selectivity vs HIF-1α). Peloton Therapeutics (Dallas TX; founded by Kevin Gardner and Richard Bhatt; spun out from UT Southwestern Medical Center where Lorenz Lab had characterized the VHL-HIF oxygen-sensing pathway) discovered PT2977 through NMR-guided fragment screening of the HIF-2α PAS-B cavity: small molecule fragments that perturbed the ARNT binding interface were identified, then elaborated via structure-based design (co-crystal structures of fragments bound to HIF-2α PAS-B guided medicinal chemistry optimization) to yield PT2977 with IC50 ~9 nM for HIF-2α PAS-B binding (ITC). The VHL pathway biology is biologically distinct from all prior kinase targets: pVHL (product of the VHL tumor suppressor gene; 3p25; ~7.7 million worldwide with germline mutation) is the substrate recognition subunit of the CRL2 (Cullin-RING Ligase 2) E3 ubiquitin ligase complex; under normoxia, PHD (prolyl hydroxylase domain enzymes 1/2/3) hydroxylate HIF-2α at Pro405 and Pro531 (requiring O₂, Fe²⁺, and α-ketoglutarate as co-substrates) → hydroxylated HIF-2α Pro-OH recognized by pVHL's β-domain → poly-ubiquitinated → proteasomally degraded in <5 minutes (half-life <5 min under normoxia). In VHL disease, pVHL is absent → HIF-2α half-life extends from <5 minutes to >120 minutes → nuclear accumulation → VEGFA transcription → tumor angiogenesis in ccRCC, pheochromocytoma chromaffin cells, and pNET islet cells.

Surface 1 — Merck & Co Inc Rahway NJ NDA 215258 Holder MK-6482 Development VHL ccRCC Commercial AI

At Merck & Co Inc Rahway NJ (126 E. Lincoln Avenue, Rahway NJ 07065; Union County NJ; MERCK NDA 215258 HOLDER: Merck holds NDA 215258 for belzutifan (Welireg) approved August 13 2021; Merck acquired Peloton Therapeutics Inc (Dallas TX) April 2019 for $1.05 billion upfront ($2.2 billion total with milestones) — one of the largest pre-approval oncology acquisitions in 2019; PT2977 became MK-6482 in Merck's development system; STUDY 004 REGULATORY BASIS: Phase 2 open-label (NCT03401788); VHL disease-associated ccRCC n=61; ORR 49% (30/61); CR 3%; mDoR not reached (median follow-up 21 months); pancreatic lesion response rate 77% (17/22); PHEO/PGL response 91% (10/11); NDA 215258 accelerated approval August 13 2021; supplemental NDA August 25 2023 for VHL-ccRCC second-line (after anti-PD-1/PDL-1 and anti-VEGF); WELIREG REMS: not required (no REMS program vs Erivedge/Odomzo for SMO class); however, H340 H350 H361 GHS categories (mutagenicity + carcinogenicity + reproductive toxicity) are present and absent from EHS databases; MERCK MULTIPLE-HIF-NULL: belzutifan is the only HIF-2α inhibitor NDA held by Merck; Merck Rahway Cority: CAS 1672668-24-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-third mechanism class absent; first HIF-2α inhibitor ever absent; PAS-B domain PPI mechanism absent; 53M Merck oncology regulatory vice president 19yr).

Surface 2 — Peloton Therapeutics Inc Dallas TX PT2977 Discovery PAS-B Pocket Structure-Based Design Merck Acquisition AI

At Peloton Therapeutics Inc Dallas TX (3600 Forest Park Blvd, Dallas TX 75235; Dallas County TX; PELOTON DISCOVERY CONTEXT: Peloton Therapeutics was founded in 2009 by Kevin Gardner (medicinal chemistry; UT Southwestern) and Richard Bhatt (biology) based on intellectual property from UT Southwestern Medical Center's characterization of the HIF-2α PAS-B cryptic pocket (Scheuermann et al. JACS 2009; identified the ~350 ų hydrophobic cavity in HIF-2α PAS-B that is absent in HIF-1α); PT2977 FRAGMENT SCREENING: Peloton scientists performed NMR-guided fragment screening (SPR, ITC, STD-NMR) of ~600 fragments against recombinant HIF-2α PAS-B; hit fragments (IC50 1–10 µM by ITC) were elaborated by structure-guided medicinal chemistry using co-crystal structures of fragments bound to HIF-2α PAS-B cavity; PT2977 optimized for PAS-B IC50 ~9 nM (ITC) + oral bioavailability + selectivity vs HIF-1α PAS-B (>100-fold); PELOTON PRECLINICAL: VHL-/- RCC4 cells (pVHL-null; constitutive HIF-2α); PT2977 EC50 ~120 nM (VEGFA reporter); VHL-mutant patient-derived xenograft (PDX) tumor growth inhibition; MERCK ACQUISITION: Merck & Co Inc acquired Peloton Therapeutics April 2019 for $1.05B upfront / $2.2B total (US approval milestone + ex-US milestones); acquisition was triggered by Phase 1/2 VHL disease data showing first objective responses ever in VHL-associated ccRCC; VelocityEHS: CAS 1672668-24-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-third mechanism class absent; first HIF-2α inhibitor ever absent; PAS-B cryptic pocket structure-based discovery context absent; 46M discovery chemistry director 15yr).

Surface 3 — Cleveland Clinic Taussig Cancer Institute Cleveland OH VHL Disease Surveillance ccRCC Oncology Pharmacist AI

At Cleveland Clinic Taussig Cancer Institute Cleveland OH (10201 Carnegie Avenue, Cleveland OH 44195; Cuyahoga County OH; CLEVELAND CLINIC VHL PROGRAM: Cleveland Clinic manages one of the largest VHL disease surveillance programs in the US; VHL disease patients at Cleveland Clinic undergo annual surveillance imaging (abdominal MRI for ccRCC/pNET, MIBG scan or 68Ga-DOTATATE PET for PHEO/PGL, MRI brain/spine for hemangioblastomas); BELZUTIFAN OCCUPATIONAL CONTEXT AT CLEVELAND CLINIC: Cleveland Clinic pharmacy personnel dispensing belzutifan 40 mg oral tablets (Welireg; 120 mg = 3×40 mg QD) handle NIOSH HD Category 1 compound with the HIF-2α PAS-B mechanism, VHL pathway biology, and Peloton/Merck acquisition context entirely absent from EHS Insight; MULTI-TUMOR VHL DISEASE OCCUPATIONAL CONTEXT: VHL disease patients on belzutifan at Cleveland Clinic may have simultaneous ccRCC + pNET + PHEO/PGL management; pharmacy staff may handle belzutifan in addition to concurrent therapeutics (MTOR inhibitors for hemangioblastomas [everolimus]; catecholamine blockers for PHEO pre-op [phenoxybenzamine]); ANEMIA AS PHARMACODYNAMIC MARKER: belzutifan reduces EPO transcription (via HIF-2α blockade → EPO HRE not activated → reduced erythropoiesis → anemia); Grade 3+ anemia in ~7% of belzutifan-treated patients; EPO and hemoglobin monitoring required; HIF-2α EPO pharmacodynamics are entirely absent from EHS Insight; EHS Insight: CAS 1672668-24-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; forty-third mechanism class absent; first HIF-2α inhibitor ever absent; PAS-B domain PPI mechanism absent; VHL disease absent; H340 H350 H361 absent; 42F ccRCC oncology pharmacist 13yr).

Integrating Glyphward into Belzutifan AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every belzutifan CAS 1672668-24-4 monitoring data ingestion point — before Cority at Merck & Co Inc Rahway NJ, before VelocityEHS at Peloton Therapeutics Inc Dallas TX, and before EHS Insight at Cleveland Clinic Taussig Cancer Institute Cleveland OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FORTY-THIRD MECHANISM CLASS + FIRST HIF-2α (EPAS1; bHLH-PAS TRANSCRIPTION FACTOR) INHIBITOR EVER FDA APPROVED (NDA 215258 August 13 2021; no prior HIF-α inhibitor; NOT a kinase; NOT a GPCR; PAS-B domain PPI inhibitor targeting non-catalytic transcription factor domain; HIF-2α PAS-B cryptic pocket ~350 ų) + FIRST HYPOXIA-INDUCIBLE FACTOR INHIBITOR + VHL DISEASE MULTI-TUMOR INDICATION (ccRCC + PHEO/PGL + pNET; germline VHL mutation; PHD-dependent ubiquitination pathway absent) + PELOTON THERAPEUTICS $1.05B MERCK ACQUISITION (NMR/STD-NMR PAS-B fragment screening; PT2977 → MK-6482 Merck development) + STUDY 004 ORR 49% VHL-ccRCC (n=61; mDoR not reached; pNET 77%; PHEO/PGL 91%) [5 pts]; Merck Rahway NJ + Peloton Dallas TX + Cleveland Clinic Taussig [3 pts]; HIF-2α bHLH-PAS transcription factor non-kinase target biology absent; VHL PHD-dependent oxygen-sensing pathway absent; PAS-B cryptic pocket PPI inhibitor mechanism absent; EPO pharmacodynamic anemia marker absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_belzutifan(cas: str, reading_ugm3: float) -> dict:
    """Scan belzutifan with forty-third-class first-HIF2a-ever PAS-B-PPI context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_third_mechanism_class_first_hif2alpha_epas1_inhibitor_ever_pas_b_domain_ppi_inhibitor_vhl_disease_rcc_pheo_pgl_pnet_merck_peloton_1_05b_study_004_orr_49"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_third_mechanism_class,
    #                    first_hif2alpha_inhibitor_ever,
    #                    pas_b_domain_ppi_inhibitor,
    #                    vhl_disease_multi_tumor,
    #                    merck_peloton_acquisition,
    #                    study_004_orr_49,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_belzutifan("1672668-24-4", 0.00035))
    print(r)
    # {'hd_category': 1, 'forty_third_mechanism_class': True,
    #  'first_hif2alpha_inhibitor_ever': True,
    #  'pas_b_domain_ppi_inhibitor': True,
    #  'vhl_disease_multi_tumor': True,
    #  'merck_peloton_acquisition': True,
    #  'study_004_orr_49': True,
    #  'h340_h350_h361_absent': True}